Renal sympathetic denervation 2024 in Austria: recommendations from the Austrian Society of Hypertension : Endorsed by the Austrian Society of Nephrology and the Working Group of Interventional Cardiology of the Austrian Society of Cardiology.
Arterial hypertension
Consensus report
Interventional therapy
Resistant hypertension
Uncontrolled hypertension
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
accepted:
21
08
2024
medline:
23
9
2024
pubmed:
23
9
2024
entrez:
23
9
2024
Statut:
ppublish
Résumé
Renal sympathetic denervation (RDN) is an interventional supplement to medical treatment in patients with arterial hypertension. While the first sham-controlled trial, SYMPLICITY HTN‑3 was neutral, with improved procedural details, patient selection and follow-up, recent randomized sham-controlled trials of second-generation devices show a consistent blood pressure lowering effect of RDN, as compared to sham controls. These new data and the recent U.S. Food and Drug Administration (FDA) premarket approval of two RDN devices are the basis for the present recommendations update.This joint position paper from the Austrian Society of Hypertension, together with the Austrian Society of Nephrology and the Working Group of Interventional Cardiology from the Austrian Society of Cardiology includes an overview about the available evidence on RDN and gives specific recommendations for the work-up, patient selection, pretreatment, procedural management and follow-up in patients undergoing RDN in Austria. Specifically, RDN may be used in clinical routine care, together with lifestyle measures and antihypertensive drugs, in patients with resistant hypertension (i.e. uncontrolled blood pressure on 3 antihypertensive drugs) and in those with uncontrolled hypertension, after adequate work-up, if institutional, patient-related and procedural conditions are fulfilled.
Identifiants
pubmed: 39311980
doi: 10.1007/s00508-024-02440-3
pii: 10.1007/s00508-024-02440-3
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Practice Guideline
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
559-569Informations de copyright
© 2024. The Author(s).
Références
Weber T, Zweiker R, Koppelstatter C, Lambert T, Brussee H, Eber B, et al. Renale Sympathikusdenervierung 2014 in Österreich: Update der Empfehlungen der Österreichischen Gesellschaft für Hypertensiologie. Austrian J Hypertens. 2014in;18(2):54–60.
Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN‑2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9. https://doi.org/10.1016/S0140-6736(10)62039-9 .
doi: 10.1016/S0140-6736(10)62039-9
Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401. https://doi.org/10.1056/NEJMoa1402670 .
doi: 10.1056/NEJMoa1402670
pubmed: 24678939
Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–65. https://doi.org/10.1016/S0140-6736(14)61942-5 .
doi: 10.1016/S0140-6736(14)61942-5
pubmed: 25631070
Desch S, Okon T, Heinemann D, Kulle K, Rohnert K, Sonnabend M, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension. 2015;65(6):1202–8. https://doi.org/10.1161/HYPERTENSIONAHA.115.05283 .
doi: 10.1161/HYPERTENSIONAHA.115.05283
pubmed: 25824248
Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160–70. https://doi.org/10.1016/S0140-6736(17)32281-X .
doi: 10.1016/S0140-6736(17)32281-X
pubmed: 28859944
Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–45. https://doi.org/10.1016/s0140-6736(18)31082-1 .
doi: 10.1016/s0140-6736(18)31082-1
pubmed: 29803590
Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6‑month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–55. https://doi.org/10.1016/s0140-6736(18)30951-6 .
doi: 10.1016/s0140-6736(18)30951-6
pubmed: 29803589
Schmieder RE, Ott C, Toennes SW, Bramlage P, Gertner M, Dawood O, et al. Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension—WAVE IV. J Hypertens. 2018;36(3):680–9. https://doi.org/10.1097/HJH.0000000000001584 .
doi: 10.1097/HJH.0000000000001584
pubmed: 29035942
Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled tria. Lancet. 2020;395(10234):1444–51. https://doi.org/10.1016/s0140-6736(20)30554-7 .
doi: 10.1016/s0140-6736(20)30554-7
pubmed: 32234534
Weber MA, Kirtane AJ, Weir MR, Radhakrishnan J, Das T, Berk M, et al. The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension. JACC Cardiovasc Interv. 2020;13(4):461–70. https://doi.org/10.1016/j.jcin.2019.10.061 .
doi: 10.1016/j.jcin.2019.10.061
pubmed: 32081240
Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476–86. https://doi.org/10.1016/S0140-6736(21)00788-1 .
doi: 10.1016/S0140-6736(21)00788-1
pubmed: 34010611
Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399(10333):1401–10. https://doi.org/10.1016/s0140-6736(22)00455-x .
doi: 10.1016/s0140-6736(22)00455-x
pubmed: 35390320
Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, et al. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial. Jama : J Am Med Assoc. 2023;329(8):651–61. https://doi.org/10.1001/jama.2023.0713 .
doi: 10.1001/jama.2023.0713
Mathiassen ON, Vase H, Bech JN, Christensen KL, Buus NH, Schroeder AP, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24‑h blood pressure-based trial. J Hypertens. 2016;34(8):1639–47. https://doi.org/10.1097/HJH.0000000000000977 .
doi: 10.1097/HJH.0000000000000977
pubmed: 27228432
pmcid: 4933576
Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res. 2022;45(2):221–31. https://doi.org/10.1038/s41440-021-00754-7 .
doi: 10.1038/s41440-021-00754-7
pubmed: 34654905
Kario K, Mahfoud F, Kandzari DE, Townsend RR, Weber MA, Schmieder RE, et al. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial. Hypertens Res. 2023;46(1):280–8. https://doi.org/10.1038/s41440-022-01042-8 .
doi: 10.1038/s41440-022-01042-8
pubmed: 36241705
Kandzari DE, Townsend RR, Kario K, Mahfoud F, Weber MA, Schmieder RE, et al. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. J Am Coll Cardiol. 2023;82(19):1809–23. https://doi.org/10.1016/j.jacc.2023.08.045 .
doi: 10.1016/j.jacc.2023.08.045
pubmed: 37914510
U. S. Food and Drug Administration. PMA P220026: Symplicity Spyral™ Renal Denervation System. In: https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220026A.pdf .
U. S. Food and Drug Administration. PMA P220023: Paradise® Ultrasound Renal Denervation System. In: https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220023A.pdf .
Mancia G, Kreutz Co-Chair R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, et al. ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023; https://doi.org/10.1097/HJH.0000000000003480 .
doi: 10.1097/HJH.0000000000003480
pubmed: 38033258
pmcid: 10712992
Barbato E, Azizi M, Schmieder RE, Lauder L, Bohm M, Brouwers S, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023;44(15):1313–30. https://doi.org/10.1093/eurheartj/ehad054 .
doi: 10.1093/eurheartj/ehad054
pubmed: 36790101
Schmieder RE, Mahfoud F, Mancia G, Azizi M, Böhm M, Dimitriadis K, et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9):1733–41. https://doi.org/10.1097/hjh.0000000000002933 .
doi: 10.1097/hjh.0000000000002933
pubmed: 34261957
Mahfoud F, Galle J, Schunkert H, Schmieder RE, Rump LC, Limbourg FP, et al. Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V.. (DGK), der Deutschen Hochdruckliga e. V. DHL®/Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie (DGfN) zur Zertifizierung von “Renale-Denervations-Zentren (RDZ)” – Update. Kardiologe. 2021;15(5):463–70. https://doi.org/10.1007/s12181-021-00492-7 .
doi: 10.1007/s12181-021-00492-7
Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension. 2004;43(2):169–75. https://doi.org/10.1161/01.HYP.0000103160.35395.9E .
doi: 10.1161/01.HYP.0000103160.35395.9E
pubmed: 14610101
Doumas M, Papademetriou V, Douma S, Faselis C, Tsioufis K, Gkaliagkousi E, et al. Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens. 2010;2011:318549. https://doi.org/10.4061/2011/318549 .
doi: 10.4061/2011/318549
pubmed: 21234402
pmcid: 3014695
Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152(16):1501–4. https://doi.org/10.1001/jama.1953.03690160001001 .
doi: 10.1001/jama.1953.03690160001001
pubmed: 13061307
Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81. https://doi.org/10.1016/S0140-6736(09)60566-3 .
doi: 10.1016/S0140-6736(09)60566-3
pubmed: 19332353
Zweiker D, Lambert T, Steinwender C, Weber T, Suppan M, Brussee H, et al. Effects of Renal Denervation Documented in the Austrian National Multicentre Renal Denervation Registry. PLoS ONE. 2016;11(8):e161250. https://doi.org/10.1371/journal.pone.0161250 .
doi: 10.1371/journal.pone.0161250
pubmed: 27529426
pmcid: 4987037
Weber T, Zweiker R, Watschinger B, Gruner P, Koppelstatter C, Brandt MC, et al. Clinical application of interventional renal sympathetic denervation: recommendations of the Austrian Society of Hypertension 2012. Wien Klin Wochenschr. 2012;124(21-22):789–98. https://doi.org/10.1007/s00508-012-0257-3 .
doi: 10.1007/s00508-012-0257-3
pubmed: 23184070
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104. https://doi.org/10.1093/eurheartj/ehy339 .
doi: 10.1093/eurheartj/ehy339
pubmed: 30165516
Howard JP, Shun-Shin MJ, Hartley A, Bhatt DL, Krum H, Francis DP. Quantifying the 3 Biases That Lead to Unintentional Overestimation of the Blood Pressure-Lowering Effect of Renal Denervation. Circ Cardiovasc Qual Outcomes. 2016;9(1):14–22. https://doi.org/10.1161/circoutcomes.115.002533 .
doi: 10.1161/circoutcomes.115.002533
pubmed: 26758193
Biffi A, Dell’Oro R, Quarti-Trevano F, Cuspidi C, Corrao G, Mancia G, et al. Effects of Renal Denervation on Sympathetic Nerve Traffic and Correlates in Drug-Resistant and Uncontrolled Hypertension: A Systematic Review and Meta-Analysis. Hypertension. 2023;80(3):659–67. https://doi.org/10.1161/HYPERTENSIONAHA.122.20503 .
doi: 10.1161/HYPERTENSIONAHA.122.20503
pubmed: 36628971
Pathak A, Rudolph UM, Saxena M, Zeller T, Muller-Ehmsen J, Lipsic E, et al. Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications. EuroIntervention. 2023;19(7):602–11. https://doi.org/10.4244/EIJ-D-23-00088 .
doi: 10.4244/EIJ-D-23-00088
pubmed: 37427416
pmcid: 10493775
Mahfoud F, Bohm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, et al. Effects of renal denervation on kidney function and long-term outcomes: 3‑year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40(42):3474–82. https://doi.org/10.1093/eurheartj/ehz118 .
doi: 10.1093/eurheartj/ehz118
pubmed: 30907413
pmcid: 6837160
Townsend RR, Walton A, Hettrick DA, Hickey GL, Weil J, Sharp ASP, et al. Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention. 2020;16(1):89–96. https://doi.org/10.4244/EIJ-D-19-00902 .
doi: 10.4244/EIJ-D-19-00902
pubmed: 32038027
Sanders MF, Reitsma JB, Morpey M, Gremmels H, Bots ML, Pisano A, et al. Renal safety of catheter-based renal denervation: systematic review and meta-analysis. Nephrol Dial Transplant : Off Publ Eur Dial Transpl Assoc Ren Assoc. 2017;32(9):1440–7. https://doi.org/10.1093/ndt/gfx088 .
doi: 10.1093/ndt/gfx088
Weber MA, Schmieder RE, Kandzari DE, Townsend RR, Mahfoud F, Tsioufis K, et al. Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial. Clin Res Cardiol. 2022;111(11):1269–75. https://doi.org/10.1007/s00392-022-02064-5 .
doi: 10.1007/s00392-022-02064-5
pubmed: 35852582
pmcid: 9622517
Singh RR, McArdle ZM, Iudica M, Easton LK, Booth LC, May CN, et al. Sustained Decrease in Blood Pressure and Reduced Anatomical and Functional Reinnervation of Renal Nerves in Hypertensive Sheep 30 Months After Catheter-Based Renal Denervation. Hypertension. 2019;73(3):718–27. https://doi.org/10.1161/HYPERTENSIONAHA.118.12250 .
doi: 10.1161/HYPERTENSIONAHA.118.12250
pubmed: 30661475
Sesa-Ashton G, Nolde JM, Muente I, Carnagarin R, Lee R, Macefield VG, et al. Catheter-Based Renal Denervation: 9‑Year Follow-Up Data on Safety and Blood Pressure Reduction in Patients With Resistant. Hypertens Hypertens. 2023;80(4):811–9. https://doi.org/10.1161/HYPERTENSIONAHA.122.20853 .
doi: 10.1161/HYPERTENSIONAHA.122.20853
Al Ghorani H, Kulenthiran S, Recktenwald MJM, Lauder L, Kunz M, Gotzinger F, et al. 10-Year Outcomes of Catheter-Based Renal Denervation in Patients With Resistant Hypertension. J Am Coll Cardiol. 2023;81(5):517–9. https://doi.org/10.1016/j.jacc.2022.11.038 .
doi: 10.1016/j.jacc.2022.11.038
pubmed: 36725181
Mahfoud F, Mancia G, Schmieder RE, Ruilope L, Narkiewicz K, Schlaich M, et al. Outcomes Following Radiofrequency Renal Denervation According to Antihypertensive Medications: Subgroup Analysis of the Global SYMPLICITY Registry DEFINE. Hypertension. 2023;80(8):1759–70. https://doi.org/10.1161/HYPERTENSIONAHA.123.21283 .
doi: 10.1161/HYPERTENSIONAHA.123.21283
pubmed: 37317866
Shishehbor MH, Hammad TA, Thomas G. Renal denervation: What happened, and why? Cleve Clin J Med. 2017;84(9):681–6. https://doi.org/10.3949/ccjm.84a.14129 .
doi: 10.3949/ccjm.84a.14129
pubmed: 28885911
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219. https://doi.org/10.1093/eurheartj/eht151 .
doi: 10.1093/eurheartj/eht151
pubmed: 23771844
Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022;400(10361):1417–25. https://doi.org/10.1016/S0140-6736(22)01786-X .
doi: 10.1016/S0140-6736(22)01786-X
pubmed: 36240838
pmcid: 9631239
Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598–605. https://doi.org/10.1161/CIRCULATIONAHA.108.830299 .
doi: 10.1161/CIRCULATIONAHA.108.830299
pubmed: 19805653
Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312(7023):71–2. https://doi.org/10.1136/bmj.312.7023.71 .
doi: 10.1136/bmj.312.7023.71
pubmed: 8555924
pmcid: 2349778
Swaminathan RV, East CA, Feldman DN, Fisher ND, Garasic JM, Giri JS, et al. SCAI Position Statement on Renal Denervation for Hypertension: Patient Selection, Operator Competence, Training and Techniques, and Organizational Recommendations. J Soc Cardiovasc Angiogr Interv. 2023; https://doi.org/10.1016/j.jscai.2023.101121 .
doi: 10.1016/j.jscai.2023.101121
pubmed: 39129887
pmcid: 11307723
Sundstrom J, Lind L, Nowrouzi S, Hagstrom E, Held C, Lytsy P, et al. Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial. Jama : J Am Med Assoc. 2023;329(14):1160–9. https://doi.org/10.1001/jama.2023.3322 .
doi: 10.1001/jama.2023.3322
Bohm M, Mahfoud F, Townsend RR, Kandzari DE, Pocock S, Ukena C, et al. Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. Eur Heart J. 2019;40(9):743–51. https://doi.org/10.1093/eurheartj/ehy871 .
doi: 10.1093/eurheartj/ehy871
pubmed: 30608521
Weber T, Wassertheurer S, Mayer CC, Hametner B, Danninger K, Townsend RR, et al. Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial. Hypertension. 2022;79(7):1506–14. https://doi.org/10.1161/HYPERTENSIONAHA.121.18641 .
doi: 10.1161/HYPERTENSIONAHA.121.18641
pubmed: 35582957
Mahfoud F, Townsend RR, Kandzari DE, Kario K, Schmieder RE, Tsioufis K, et al. Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. J Am Coll Cardiol. 2021;77(23):2909–19. https://doi.org/10.1016/j.jacc.2021.04.044 .
doi: 10.1016/j.jacc.2021.04.044
pubmed: 33957242
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019;41(3):407–77. https://doi.org/10.1093/eurheartj/ehz425 .
doi: 10.1093/eurheartj/ehz425
Zweiker D, Lambert T, Steinwender C, Weber T, Suppan M, Brussee H, et al. Blood pressure changes after renal denervation are more pronounced in women and nondiabetic patients: findings from the Austrian Transcatheter Renal Denervation Registry. J Hypertens. 2019;37(11):2290–7. https://doi.org/10.1097/HJH.0000000000002190 .
doi: 10.1097/HJH.0000000000002190
pubmed: 31335512